�ڰ�������

High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients with Obesity

LiverMultiScan shown to be the best non-invasive predictor of disease activity in autoimmune hepatitis, demonstrating its potential to influence clinical treatment.

�ڰ������� Lands Top Spot in Alantra Pharma Fast 50 Rankings

New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials.

UVA Health First Hospital in the State to Offer LiverMultiScan for Non-Invasive Assessment of Liver Disease

�ڰ������� launches study to improve outcomes for patients with liver cancer

World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA

FDA awards funding to �ڰ������� and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease